Vectus Biosystems Limited (ASX:VBS)
Australia
· Delayed Price · Currency is AUD 0.125
0.00 (0.00%)
Mar 10, 2026, 11:25 AM AEST
Vectus Biosystems Revenue
Vectus Biosystems had revenue of 5.49K AUD in the half year ending December 31, 2025, a decrease of -99.15%. This brings the company's revenue in the last twelve months to 89.96K, down -89.83% year-over-year. In the fiscal year ending June 30, 2025, Vectus Biosystems had annual revenue of 478.18K, down -58.01%.
Revenue (ttm)
89.96K
Revenue Growth
-89.83%
P/S Ratio
74.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 478.18K | -660.49K | -58.01% |
| Jun 30, 2024 | 1.14M | -215.86K | -15.94% |
| Jun 30, 2023 | 1.35M | 54.45K | 4.19% |
| Jun 30, 2022 | 1.30M | 282.09K | 27.71% |
| Jun 30, 2021 | 1.02M | 966.81K | 1,888.82% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zelira Therapeutics | 656.00 |
| Acrux | 2.81M |
| Biotron | -868.00 |
| Nexalis Therapeutics | 761.96K |
| Chimeric Therapeutics | 9.75M |
| Invex Therapeutics | 229.08K |
| Immuron | 7.48M |
| Tissue Repair | 3.38M |
Vectus Biosystems News
- 4 weeks ago - XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars - Nasdaq